The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing.
暂无分享,去创建一个
Martin Eklund | Johan Lindberg | Fredrik Wiklund | Tobias Nordström | Henrik Grönberg | Mark Clements | Lars Egevad | J. Lindberg | H. Grönberg | M. Eklund | F. Wiklund | J. Adolfsson | P. Wiklund | Y. Brandberg | M. Aly | M. Clements | L. Egevad | T. Nordström | Jan Adolfsson | Yvonne Brandberg | Markus Aly | J. Presti | Peter Wiklund | Joseph C Presti | James Thompson | Mark StLezin | J. Thompson | Mark StLezin
[1] Martin Eklund,et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. , 2015, The Lancet. Oncology.
[2] J. Hugosson,et al. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. , 2015, European urology.
[3] Tobias Nordström,et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. , 2013, European urology.